Zura Bio expands HS trial to 225 patients; expects Q4 2026 data; cash through 2027

Zura Bio Ltd

Phase 2 TibuSHIELD trial in HS expanded from 180 to 225 participants; topline data expected Q4 2026.
Phase 2 TibuSURE trial in SSc: topline data anticipated in first half of 2027.
Cash and equivalents sufficient to fund operations through 2027, beyond both data readouts.
Tibulizumab is a first-in-class bispecific antibody targeting IL-17 and BAFF pathways.

item 7.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001104659-26-002688
form_type: 8-K
ticker: ZURA
cik: 0001855644
company_name: Zura Bio Ltd
filed_at: 2026-01-12T23:59:59+00:00
discovered_at: 2026-05-14T18:02:36.566449+00:00
generated_at: 2026-05-16T10:57:13.223308+00:00
sec_items: ["7.01", "8.01", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.5
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001104659-26-002688
json_url: https://secwatch.observer/filing/0001104659-26-002688.json
markdown_url: https://secwatch.observer/filing/0001104659-26-002688.md
text_url: https://secwatch.observer/filing/0001104659-26-002688.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1855644/000110465926002688/0001104659-26-002688-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1855644/000110465926002688/tm262894d1_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001104659-26-002688

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.